Skip to Main Content


Skip Nav Destination


In This Issue

In The Spotlight


Research Articles

A phase Ib trial of ficlatuzumab and cytarabine in high-risk AML reports a favorable safety profile and promising clinical activity. Multidimensional single-cell analyses collected before and after therapy identify several candidate prospective and pharmacodynamic biomarkers of response.

Close Modal

or Create an Account

Close Modal
Close Modal